Andelyn Biosciences partnered with ENCell to build a manufacturing bridge connecting the United States and Asia-Pacific for cell and gene therapy programs. The companies said the collaboration is designed to streamline a “dual hemisphere” workflow that supports in-country manufacturing for local clinical trials. The partnership leverages GMP capacity at both contract development and manufacturing organizations and uses regional networks to reduce regulatory and logistical friction during global expansion. For sponsors, the structure aims to shorten lead times and improve responsiveness to country-specific patient and trial needs, addressing one of the recurring bottlenecks in CGT scaling.